Compare

Revium Rx. vs Xenetic Biosciences, Inc. vs GT Biopharma, Inc. vs Palatin Technologies Inc

Latest annual figures from SEC filings. Each company is shown for its own most recent fiscal year, so period ends can differ. Select a figure to see its full history.

Latest fiscal yearRevium Rx.
RVRC
Xenetic Biosciences, Inc.
XBIO
GT Biopharma, Inc.
GTBP
Palatin Technologies Inc
PTN
Year ended2025-12-312025-12-312025-12-312026-06-30
Revenuen/a$2.98Mn/a$13.19M
Revenue growth (YoY)n/a+19.0%n/an/a
Gross marginn/an/an/an/a
Operating marginn/a-95.2%n/a-65.7%
Net marginn/a-90.1%n/a-63.5%
Net income-$13.45M-$2.68M-$28.35M-$8.38M
EPS (Diluted)-$0.22-$1.58-$6.68-$2.96
Operating cash flown/a-$2.29M-$12.91M-$13.53M
Free cash flown/an/an/a-$13.58M
Cash & equivalents$1.68Mn/a$6.81M$7.49M
Total assets$8.30M$8.36M$8.11M$8.52M
Total liabilities$1.42M$968.0Kn/a$1.84M
Shareholders' equity$6.88M$7.40M$5.79M$6.69M
Return on year-end equity-195.5%-36.2%-490.0%-125.3%
Shares outstanding60.73M2.29M25.53M1.78M

n/a means the company did not report that line under the concept TickerFacts maps, not that it is zero.

Revenue, most recent five fiscal years

Fiscal yearRevium Rx.Xenetic Biosciences, Inc.GT Biopharma, Inc.Palatin Technologies Inc
Latestn/a$2.98M
Ended 2025-12-31
$0
Ended 2020-12-31
$13.19M
Ended 2026-06-30
1 year earliern/a$2.50M
Ended 2024-12-31
$0
Ended 2019-12-31
n/a
2 years earliern/a$2.54M
Ended 2023-12-31
n/an/a
3 years earliern/a$1.71M
Ended 2022-12-31
n/an/a
4 years earliern/a$1.16M
Ended 2021-12-31
n/an/a